SEC Form 4 · accession 0001179110-18-002255
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — President and CEO · Director
Period of report
Feb 14, 2018
Accepted (ET)
Feb 16, 2018 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $18.41 | Feb 14, 2018 | A | 201,552 | A | Feb 14, 2019 | Feb 14, 2028 | Common Stock | 201,552 | 201,552 | D |
| Restricted Stock UnitsF2 | $0.00 | Feb 14, 2018 | A | 114,918 | A | Feb 14, 2019 | — | Common Stock | 114,918 | 114,918 | D |
Explanation of responses
- F1This option vests one-fourth on such date and then 1/48th monthly thereafter.
- F2This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.